D.E. Shaw & Co
STLN

D.E. Shaw & Co’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

D.E. Shaw & Co’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-124,360
Closed -$1.23M – 5722
2021
Q3 		$1.23M Hold
124,360
– – ﹤0.01% 3434
2021
Q2 		$1.24M Buy
+124,360
New +$1.25M ﹤0.01% 3366

Other funds holding STLN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
PGM
Parian Global Management Pound Ridge, New York $30.8M AUM 51.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TM
Triatomic Management Palo Alto, California $3.39M AUM 3.35% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

D.E. Shaw & Co's STLN Position: Q4 2021 in Review

D.E. Shaw & Co sold out of Starling Oncology Institute, Inc. Common Stock (STLN) in Q4 2021, closing a stake of 124,360 shares — an estimated $1.23M sold.

D.E. Shaw & Co first reported a position in STLN in Q2 2021 and held it in 2 quarters. The position peaked at $1.24M in Q2 2021. 21 funds tracked by Wall St. Rank hold STLN as of Q4 2021.

  • D.E. Shaw & Co reported no remaining Starling Oncology Institute, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • D.E. Shaw & Co sold 124,360 Starling Oncology Institute, Inc. Common Stock shares in Q4 2021, an estimated $1.23M.
  • D.E. Shaw & Co first reported a position in Starling Oncology Institute, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • D.E. Shaw & Co's Starling Oncology Institute, Inc. Common Stock position peaked at $1.24M in Q2 2021.
  • 21 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q4 2021.

Based on D.E. Shaw & Co's 13F filing for Q4 2021, filed 14 Feb 2022.